CERUS CORP (CERS)

US1570851014 - Common Stock

1.88  +0.09 (+5.03%)

Fundamental Rating

2

CERS gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 196 industry peers in the Health Care Equipment & Supplies industry. CERS has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, CERS is valued expensive at the moment.



1

1. Profitability

1.1 Basic Checks

In the past year CERS has reported negative net income.
CERS had a negative operating cash flow in the past year.
In the past 5 years CERS always reported negative net income.
In the past 5 years CERS always reported negative operating cash flow.

1.2 Ratios

The Return On Assets of CERS (-18.96%) is comparable to the rest of the industry.
The Return On Equity of CERS (-71.22%) is worse than 61.73% of its industry peers.
Industry RankSector Rank
ROA -18.96%
ROE -71.22%
ROIC N/A
ROA(3y)-20.5%
ROA(5y)-26.31%
ROE(3y)-66.27%
ROE(5y)-76.24%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

CERS has a better Gross Margin (62.54%) than 62.76% of its industry peers.
In the last couple of years the Gross Margin of CERS has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for CERS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 62.54%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.77%
GM growth 5Y1.4%

1

2. Health

2.1 Basic Checks

CERS does not have a ROIC to compare to the WACC, probably because it is not profitable.
CERS has more shares outstanding than it did 1 year ago.
The number of shares outstanding for CERS has been increased compared to 5 years ago.
CERS has a worse debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of -5.08, we must say that CERS is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -5.08, CERS is doing worse than 69.90% of the companies in the same industry.
CERS has a Debt/Equity ratio of 1.14. This is a high value indicating a heavy dependency on external financing.
CERS has a Debt to Equity ratio of 1.14. This is amonst the worse of the industry: CERS underperforms 81.63% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.14
Debt/FCF N/A
Altman-Z -5.08
ROIC/WACCN/A
WACC10.26%

2.3 Liquidity

CERS has a Current Ratio of 2.14. This indicates that CERS is financially healthy and has no problem in meeting its short term obligations.
CERS has a Current ratio of 2.14. This is in the lower half of the industry: CERS underperforms 71.94% of its industry peers.
A Quick Ratio of 1.55 indicates that CERS should not have too much problems paying its short term obligations.
CERS's Quick ratio of 1.55 is on the low side compared to the rest of the industry. CERS is outperformed by 69.39% of its industry peers.
Industry RankSector Rank
Current Ratio 2.14
Quick Ratio 1.55

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 24.00% over the past year.
CERS shows a decrease in Revenue. In the last year, the revenue decreased by -0.80%.
Measured over the past years, CERS shows a quite strong growth in Revenue. The Revenue has been growing by 19.67% on average per year.
EPS 1Y (TTM)24%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q87.5%
Revenue 1Y (TTM)-0.8%
Revenue growth 3Y17.82%
Revenue growth 5Y19.67%
Revenue growth Q2Q3.94%

3.2 Future

The Earnings Per Share is expected to grow by 29.53% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 20.64% on average over the next years. This is a very strong growth
EPS Next Y39.87%
EPS Next 2Y29.53%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year13.63%
Revenue Next 2Y13.12%
Revenue Next 3Y20.64%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CERS. In the last year negative earnings were reported.
Also next year CERS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

CERS's earnings are expected to grow with 29.53% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.53%
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

CERS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

CERUS CORP

NASDAQ:CERS (3/28/2024, 11:59:28 AM)

1.88

+0.09 (+5.03%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap340.81M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -18.96%
ROE -71.22%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM 62.54%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.94
Health
Industry RankSector Rank
Debt/Equity 1.14
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 2.14
Quick Ratio 1.55
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)24%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y39.87%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-0.8%
Revenue growth 3Y17.82%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y